Navigation Links
New Incentives to Help Combat Antimicrobial Resistance, but Overuse of Strong Antibiotics Still Needs to Be Curbed
Date:7/12/2012

ROUND ROCK, Texas, July 12, 2012 /PRNewswire/ -- The FDA Safety Innovation Act (FDASIA), signed yesterday, provides pharmaceutical manufacturers with an extended window of antibiotic formulary exclusivity. This incentive should increase drug innovation, but it doesn't address increasing antimicrobial drug resistance, according to noted expert, Dr. David Khan of The University of Texas Southwestern Medical Center in Dallas.

"Too often, a patient's self-reported penicillin allergy causes broad antibiotics to be prescribed even though penicillin was the most appropriate treatment. However, studies show in nine out of ten cases, patients reporting a penicillin allergy are non-allergic," said Dr. Khan.

"Test before treating with non-penicillin antibiotics. With a simple, quick allergy skin test, doctors can easily and inexpensively determine if penicillin is an option," said Dr. Roland Solensky of the Corvallis Clinic.

"Overuse of broad spectrum antibiotic leads to antimicrobial resistance and the need for more powerful antibiotics, which have more toxic side effects," said Dr. Solensky, who wrote the drug allergy practice guidelines.

"By denying a potentially effective treatment, these patients are susceptible to the overuse of broad spectrum antibiotics, leading to increased drug-resistant bacteria," said Jose A. Moreno Toscano, President of ALK-Abello, Inc.

PRE-PEN® (benzylpenicilloyl polylysine injection USP), a skin test product widely used for more than 30 years, can help medical staff quickly identify patients who can safely receive penicillin, opening up a wider range of options and saving lives in the process.

About ALK
ALK holds worldwide rights to market and distribute PRE-PEN® (benzylpenicilloyl polylysine injection USP) penicillin skin testing product. PRE-PEN® (benzylpenicilloyl polylysine injection USP) is currently approved and sold in the USA and Canada.

ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy), a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. The company has approximately 1,400 employees with subsidiaries, production facilities and distributors worldwide. ALK was named one of the Best Companies to Work for in Texas in 2012 by www.BestCompaniesTX.com. Further information is available at www.alk-abello.us.

Contact Information:
Lisa Lawrence
For ALK
512-426-4904
Lisa.Lawrence@hcbhealth.com


'/>"/>
SOURCE ALK
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
2. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
3. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. UN emission market needs urgent reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... of drug and device development, and Prism Clinical Research , a leader ... announced Verified Clinical Trials (VCT) has been selected by both companies ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a ... or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed ... business-card sized form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Clinical Ops Executives 2017 in its continued commitment to the advancement of the ... to discuss current issues related to clinical trial planning and management. , ...
(Date:1/18/2017)... ... January 18, 2017 , ... Researchers from a new study are stating ... low enough after prostate cancer treatment, this indicates there is still remaining prostate cancer cells ... , “ The PSA test has always been an indicator of whether a man’s prostate ...
Breaking Biology Technology:
(Date:12/15/2016)... -- ... Research and Markets has announced the addition of the "Global Military ... report forecasts the global military biometrics market to grow at a CAGR ... been prepared based on an in-depth market analysis with inputs from industry ... the coming years. The report also includes a discussion of the key ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , the ... of its patent portfolio, which grew to over 40 granted and pending ... , , ... filed patent entitled " System, Device, and Method Estimating Force ... enables device makers to forego costly hardware components needed to estimate the ...
Breaking Biology News(10 mins):